

15TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Wednesday, 28th September 2022, Lansdowne Suite, Herbert Park Hotel

Registration from 12:30

CPD: 3 external points

13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, UCLA

- 13:45 – 14:15 **Identifying novel targets and targeted therapies for breast cancer**
Prof. Sara Hurvitz, Professor of Medicine and Director, Breast Cancer Clinical Trials Program, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA. Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center.
- 14:15 – 14:45 **Therapeutic application of ADCs: challenging the current breast cancer classification**
Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston
- 14:45 – 15:15 **Beyond ADCs - Next Generation Targeted Therapeutics**
Dr. Richard Markus, President and CEO, Dantari
- 15:15 – 15:30 *Coffee break*

KEYNOTE PRESENTATION

- 15:30 - 16:15 **Identifying novel targets and targeted therapies for cancer**
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology and Executive Vice Chair for Research, Department of Medicine, UCLA.

TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, UCLA

- 16:15 - 16:45 **Development of a novel therapeutic mAb and ADC for the treatment of CLDN18.2-positive cancers**
Dr. Neil O'Brien, Adjunct Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA
- 16:45 – 17:15 **Targeting Acetyl-CoA-carboxylase in breast cancer**
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE THE #TRANSONCXV

15TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Thursday, 29th September 2022, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30

CPD: 5 external points

TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto

- 09:00 - 09:30 **Preclinical modelling of ‘authentic’ acquired resistance to immune checkpoint antibody blockade**
Prof Bob Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto
- 09:30 - 10:00 **Effects of arenavirus-based immuno-virotherapy on the tumor microenvironment (TME): inducing tumor-destroying immune effects**
Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics
- 10:00 - 10:30 **Clinical development of Olinvacimab and PMC-403 and their scientific rationale**
Dr. Jin-San Yoo, President & CEO, PharmAbcine, Inc
- 10:30 - 10:45 *Coffee break*

TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto

- 10:45 - 11:15 **The immunological host response to immunotherapy: Towards biomarker discovery and therapeutic opportunities.**
Prof Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center.
- 11:15 – 11:45 **Targeting the metastatic niche**
Prof Janine Erler, Professor in Cancer Biology, Biotech Research and Innovation Centre, University of Copenhagen, Denmark
- 11:45 – 12:15 **Stromal fibroblasts sculpt tumour evolution and therapy responses**
Dr. Erik Sahai, Principal Group Leader, Assistant Research Director, The Francis Crick Institute, London

KEYNOTE PRESENTATION

- 12:15 – 13:00 **Development of novel ubiquitin system-based anti cancer drugs.**
Prof. Aaron Ciechanover, 2004 Nobel Laureate, Distinguished Professor, Technion-Israel Institute of Technology
- 13:00 - 14:00 *Lunch*

TARGETING DIFFICULT TO DRUG GENES FOR CANCER THERAPY

Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin

- 14:00 - 14:30 **Targeting "Undruggable" Genes: Update 2022**
Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
- 14:30 – 15:00 **Developing a clinically viable MYC inhibitor for cancer treatment**
Prof Laura Soucek, Group Leader, VHIO Models of Cancer Therapies Group, Spain
- 15:00 - 15:30 **Sotorasib, the first approved KRAS inhibitor**
John Waldron, Medical Science Liaison (Haematology/Oncology), Amgen Ireland
- 15:30 - 15:45 *Coffee break*

IO THERAPIES : Session Chair – Prof John Crown, St. Vincent’s University Hospital

- 15:45 - 16:15 **The Evolution of Neoadjuvant Immunotherapy for Lung Cancer - Translational Science to Clinical Results**
Dr. Patrick Forde, Assoc Prof Oncology, Johns Hopkins University, Baltimore
- 16:15 - 16:45 **Advances in CAR T cell Therapies for Solid Tumors**
Prof. Roisin O’Cearbhaill, Research Director, Gynecologic Medical Oncology Service, MSKCC
- 16:45 - 17:15 **Hepatobiliary Cancers: Clinical/ Scientific Advances and Unmet Needs**
Dr. Richard Finn, Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE THE #TRANSONCXV

15TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Friday 30th September 2022, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30

CPD: 3 external points

NOVEL TARGETED DRUGS & BIOMARKERS: Session Chair - Prof William Gallagher, University College Dublin

09:00 - 09:30 **Mapping the degradation landscape in cancer reveals insight into anti-tumor immunity**
Dr. Yifat Merbl, Senior Scientist, Weizmann Institute of Science, Israel

09:30 - 10:00 **Clinical validation of conceptually novel anti-hypoxia A2-adenosinergic immunotherapies in cancer patients who were otherwise refractory to all other current treatments**
Prof Michail Sitkovsky, E.W.Black Chair, Prof Immunophysiology & Pharmaceutical Biotechnology, Director, New England Inflammation & Tissue Protection Institute, Northeastern University, Boston

10:00 - 10:30 **Using the immune system to detect cancer**
Prof. Josh LaBaer, Executive Director, Biodesign Institute, Arizona State University

10:30 – 10:45 *Coffee break*

ANTIBODY DRUG CONJUGATES: Session Chair - Prof John Crown, St. Vincent's University Hospital

10:45-11:15 **Advancing Trop-2 directed ADCs into breast cancer and beyond**
Dr. See Phan, VP, Clinical Research Oncology, Gilead Sciences

11:15 – 11:45 **Development of Antibody-Drug-Conjugates: Current and future outlook**
Dr. Rodney Smith, Head of European Medical Affairs Oncology, Daiichi-Sankyo

11:45 - 12:15 **Translating the Antitumor Activity of Enfortumab Vedotin to Enable a Novel Option for Patients with NMIBC**
Dr. Christopher Carosino, Associate Director, Toxicology, PADCEV Translational Sciences Lead, Investigative Toxicology Group Lead, Seagen

12:15 – 13:15 *Lunch*

CANCER IMMUNOTHERAPY I: Session Chair – Prof. Mario Sznol, Yale

13:15 - 13:45 **The Future of Immunotherapy in Melanoma: LAG-3 and Beyond**
Dr. Giuseppe Gullo, Sr. Director, Clinical Sciences, Oncology, Regeneron

13:45 - 14:15 **Bench to bedside trials in uveal melanoma at Sylvester Cancer Center**
Dr. Jose Lutzky, Leader, Cutaneous & Ocular Oncology Site Disease Group Medical Director, Clinical Trials Office, Prof Clinical Medicine, University of Miami Sylvester Comprehensive Cancer Center.

14:15 - 14:45 **Topic: Identifying new targets and how to generate new ImmTAX**
Dr. Peter Molloy, Director of Protein Engineering in Research, Immunocore

14:45 – 15:00 *Coffee break*

CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale

15:00 – 15:30 **Anti-CD47 plus trastuzumab induces macrophage phagocytosis (ADCP) of HER2-positive breast cancer cells selected for tolerance to trastuzumab-mediated ADCC.**
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine

15:30 – 16:00 **Results of a RCT phase 3, comparing ipilimumab with TIL therapy for advanced stage melanoma having failed anti-PD-1**
Prof. Dr. John. B.A.G. Haanen, Medical Oncology Department, Netherlands Cancer Institute

16:00 – 16:30 **Designing and delivering next-generation TCR T-cell therapies**
Dr. Joanna Brewer, Chief Scientific Officer, Adaptimmune LLC

16:30 – 17:00 **Topic: IL-2 ortholog**
Dr. Martin Oft, Chief Development Officer, Synthekine

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE THE #TRANSONCXV